
FDA Accepts New Drug Application for Merck’s HIV Treatment, Doravirine/Islatravir
Merck’s investigational HIV therapy, doravirine/islatravir (DOR/ISL), has had its new drug application accepted by the FDA and has a PDUFA target date set for the spring of next year (April 28). “The health needs of people living with HIV often …